Generation of mumps virus vaccine vectors for heterologous antigens.

Informations projet

MUMPS VIRUS VECTORS

N° de convention de subvention: QLK2-CT-2000-60049

Projet clôturé

Date de début 13 Mai 2002

Date de fin 12 Mai 2006

Financé au titre de

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Coût total € 192 000,00

Contribution de l’UE € 192 000,00

Coordonné par

PIERRE FABRE MEDICAMENT S.A.
France

Objectif

Generation from cDNA of recombinant Mumps viruses capable of expressing one or more metrologies antigens; molecular, biochemical and immunologist characterisation of rescued viruses; determination of the vaccine potential of the recombinant Mumps virus vectors.

Champ scientifique

• natural sciences › biological sciences › microbiology › virology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thème(s)

• 1.1.1.-2. - Key action Control of Infectious Diseases

Appel à propositions

Data not available

Régime de financement

BUR - Bursaries, grants, fellowships

Coordinateur

PIERRE FABRE MEDICAMENT S.A.

• Contribution de l’UE: Aucune donnée
• Adresse: Avenue Napoléon III , 5 Le Puy Saint Martin ; 74164 SAINT JULIEN-EN-GENEVOIS ; France
• Coût total: Aucune donnée